TLR4 and chronic obstructive pulmonary disease: Moreover, treatment with the TLR4 inhibitor TAK-242 suppressed the overactivation of the NF-κB and MAPK signaling pathways, indicating that HSC modulates these downstream pathways through TLR4 binding, thereby reducing inflammation and contributing to COPD treatment.